Differences in compliance patterns across the selective serotonin reuptake inhibitors (SSRIs)

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Health Services Research

Background:

• Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for depression and anxiety disorders.
• Patient compliance with antidepressant therapy is crucial for treatment efficacy and outcomes.
• Differential compliance rates between immediate-release (IR) and controlled-release (CR) formulations of SSRIs may impact treatment success.

Purpose of the Study:

• To compare the 6-month compliance rates of patients initiating SSRI therapy with either IR or CR formulations.
• To identify specific SSRI agents associated with higher or lower compliance rates.

Main Methods:

• Retrospective analysis of 116,090 patients initiating SSRI therapy between July 2001 and December 2002.
• Logistic regression models were used to assess 6-month compliance rates, adjusting for demographic and clinical factors.
• Compliance was defined as an 80% medication possession ratio over 180 days without a significant gap.

Main Results:

• Overall, 54.2% of patients were noncompliant with SSRI therapy over a 6-month period.
• Patients initiating IR SSRIs were 14% less likely to be compliant compared to those initiating paroxetine CR.
• Compliance varied significantly by specific SSRI agent, with IR paroxetine showing the lowest compliance rates.

Conclusions:

• A majority of patients initiating SSRI therapy exhibit noncompliance, particularly with IR formulations.
• Controlled-release SSRI formulations appear to offer better patient compliance.
• Further research is needed to evaluate the economic impact and resource utilization associated with SSRI compliance.